Barclays analyst Matt Miksic maintains $Globus Medical (GMED.US)$ with a buy rating, and maintains the target price at $100.
According to TipRanks data, the analyst has a success rate of 62.0% and a total average return of 7.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Globus Medical (GMED.US)$'s main analysts recently are as follows:
Globus Medical is poised to achieve mid-to-high single-digit sales growth and mid-30's EBITDA margins. The company's earnings have been notably strong, driven by robust sales performance and increasing cost synergies.
Globus Medical has consistently outperformed by delivering results that surpass expectations and has shown adept management of the NuVasive integration, surpassing initial predictions. This improved execution and enhanced profitability justify a less conservative valuation multiple. Despite the positive outlook, there are reservations about the ease of realizing cross-selling synergies, particularly in the face of new competitors in the spine robot market anticipated this quarter, which may pose a challenge to achieving the projected 7% growth rate.
Q3 has served as a further significant confirmation of the view that Globus Medical's business stands on a more solid foundation than most anticipated. Moving forward, it's believed that current estimates may be too conservative and that valuations have the potential to increase.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
